Antimicrobial Stewardship Strategies Including Point-of-Care Testing (POCT) for Pediatric Patients with Upper-Respiratory-Tract Infections in Primary Care: A Systematic Review of Economic Evaluations.
C-reactive protein tests
children
health–economic evaluations
nucleic acid amplification tests
point-of-care tests
primary care
rapid antigen-detection tests
upper-respiratory-tract infections
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
22 Aug 2022
22 Aug 2022
Historique:
received:
27
07
2022
revised:
12
08
2022
accepted:
19
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Upper-respiratory-tract infections (URTIs) are among the main causes of antibiotic prescriptions in pediatric patients. Over one-third of all antibiotic prescriptions for URTIs in children are estimated to be inappropriate, as the majority of URTIs are caused by viral agents. Several strategies, including clinical scoring algorithms and different point-of-care tests (POCTs) have been developed to help discriminate bacterial from viral URTIs in the outpatient clinical setting. A systematic review of the literature was conducted following PRISMA guidelines with the objective of summarizing evidence from health-economic evaluations on the use of POCT for URTIs in pediatric outpatients. A total of 3375 records identified from four databases and other sources were screened, of which 8 met the inclusion criteria. Four studies were classified as being of high reporting quality, and three were of medium quality. Five out of eight studies concluded in favor of strategies that included POCTs, with an additional study finding several POCTs to be cost-effective compared to usual care but over an acceptable WTP threshold. This review found POCT could be a valuable tool for antimicrobial stewardship strategies targeted towards childhood URTIs in primary care.
Identifiants
pubmed: 36010008
pii: antibiotics11081139
doi: 10.3390/antibiotics11081139
pmc: PMC9404955
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Antimicrob Resist Infect Control. 2018 Oct 4;7:119
pubmed: 30323922
Lancet. 2013 Oct 5;382(9899):1175-82
pubmed: 23915885
J Eval Clin Pract. 2011 Dec;17(6):1059-69
pubmed: 20666881
Antimicrob Resist Infect Control. 2020 Jan 3;9(1):3
pubmed: 31911831
Eur J Pediatr. 2011 Aug;170(8):1059-67
pubmed: 21308380
J Clin Microbiol. 2017 Mar;55(3):715-723
pubmed: 28031432
Health Technol Assess. 2020 Jun;24(31):1-232
pubmed: 32605705
JAMA Pediatr. 2014 Nov;168(11):1073-4
pubmed: 25264869
Antibiotics (Basel). 2020 Sep 16;9(9):
pubmed: 32948060
J Hosp Infect. 2008 Apr;68(4):372-4
pubmed: 18353500
Pediatrics. 2011 Dec;128(6):1053-61
pubmed: 22065263
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32161094
Pharmacoecon Open. 2021 Jun;5(2):157-173
pubmed: 33405188
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9
pubmed: 16355321
Pediatrics. 2020 Sep;146(3):
pubmed: 32747473
Infect Control Hosp Epidemiol. 2020 May;41(5):579-584
pubmed: 32043437
J Family Med Prim Care. 2019 Sep 30;8(9):2942-2949
pubmed: 31681672
Pediatrics. 2006 Mar;117(3):609-19
pubmed: 16510638
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Med Econ. 2020 Jul;23(7):673-682
pubmed: 32259465
Medicine (Baltimore). 2020 Jan;99(2):e18714
pubmed: 31914082
Pediatrics. 2010 Sep;126(3):e557-64
pubmed: 20696723
Am J Infect Control. 2021 Dec;49(12):1543-1546
pubmed: 34358544
JAMA. 2016 May 3;315(17):1864-73
pubmed: 27139059
JAMA Netw Open. 2022 Jun 1;5(6):e2216162
pubmed: 35679047
BMC Pediatr. 2019 Jan 16;19(1):24
pubmed: 30651115
Am J Manag Care. 2021 May 1;27(5):e157-e163
pubmed: 34002967
Value Health. 2022 Jan;25(1):10-31
pubmed: 35031088
Lancet Glob Health. 2016 Sep;4(9):e586-7
pubmed: 27495136
Ann Intern Med. 2001 Mar 20;134(6):509-17
pubmed: 11255530
Am Fam Physician. 2013 Sep 1;88(5):338-40
pubmed: 24010402
Pediatrics. 2018 Jun;141(6):
pubmed: 29793986